JNJ vs PRAX

Johnson & Johnson (JNJ) remains a fundamentally strong, diversified healthcare conglomerate with an impressive market capitalization. While possessing robust financials, wide economic moats, and consistent performance, its sheer size ($579.46B) fundamentally misaligns with the criteria for 10x growth within a 3-5 year timeframe. A 10x return would necessitate a market cap exceeding $5.7 trillion, ...

Praxis Precision Medicines continues to advance its promising CNS pipeline, notably with the presumed NDA submission for PRAX-118 by end of 2025, a significant de-risking event reflected in its increased market cap to $8.97B. The company targets large, underserved markets (Essential Tremor, Epilepsies) with strong IP and novel mechanisms. While financial health remains a key watchpoint as a pre-co...